OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
42
Results
Show all
Save search
Copy query
Show results for
Unknown
(42)
Publication Date
Release Date
2020
(5)
2016
(5)
2018
(4)
2017
(4)
2022
(3)
2021
(3)
2019
(3)
2015
(3)
2014
(3)
2023
(2)
2012
(2)
2025
(1)
2024
(1)
2013
(1)
2010
(1)
2009
(1)
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.
Not available
S-EPMC4184913
|
biostudies-literature
Cite
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Not available
S-EPMC5559878
|
biostudies-literature
Cite
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
Not available
S-EPMC6276905
|
biostudies-literature
Cite
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
Not available
S-EPMC9847521
|
biostudies-literature
Cite
Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
Not available
S-EPMC7738423
|
biostudies-literature
Cite
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.
Not available
S-EPMC4040006
|
biostudies-literature
Cite
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
Not available
S-EPMC9250488
|
biostudies-literature
Cite
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
Not available
S-EPMC2783335
|
biostudies-literature
Cite
EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.
Not available
S-EPMC4608240
|
biostudies-literature
Cite
Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates.
Not available
S-EPMC11671773
|
biostudies-literature
Cite
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets